jmt103
Bone Metastases From Solid Tumors
Shanghai JMT-Bio Inc.Phase 1Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 39/ 100
- Competitive Position
- 95/ 100
Competitive context
33 Active assets in the Bone Metastases From Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zoledronate Kelly Fitzgerald, MD | Phase 4 | BBB |
Ibandronate Kelly Fitzgerald, MD | Phase 4 | BBB |
Denosumab Kelly Fitzgerald, MD | Phase 4 | BBB |
RADIUM RA-223 University of California, San Francisco | Phase 3 | BB |
Zometa Sun Yat-sen University | Phase 4 | BB |
View all 50 →
Same molecule, other indications
jmt103 is also rated in:
Imaging Examination Shows at Least One Site With Bone Metastases From Soild TumorsDormant
NR
Indicative ·
/ 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →